Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women

Matthew M Drake, Louise K. McCready, Kelley A. Hoey, Elizabeth J. Atkinson, Sundeep Khosla

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Context: It has recently been proposed that the increase in bone resorption after the menopause may not be due principally to estrogen deficiency but rather to the concomitant increase in circulating FSH levels. Objective: The objective of the study was to test whether suppression of FSH secretion in postmenopausal women reduces levels of bone resorption markers. Design: This was a prospective study. Setting: The study was conducted at a clinical research unit. Participants and Interventions: Postmenopausal women were treated with a GnRH agonist (leuprolide acetate, 7.5 mg im every 28 d; n = 21) or placebo injections (control; n = 20). Both groups received the aromatase inhibitor, letrozole, 2.5 mg/d, to eliminate variations in endogenous estrogen levels as a confounder. Main Outcome Measures: Serum FSH and bone resorption markers [serum C-terminal telopeptide of type I collagen (CTX) and tartrate-resistant acid phosphatase 5b (TRAP5b)] at d 105 (3.5 months) of treatment as compared with baseline. Results: Compared with baseline, serum FSH levels did not change significantly in controls (+6%) but were reduced (-86%, into the premenopausal range) in the GnRH group. Due to the aromatase inhibitor-induced reduction in estrogen production, serum CTX and TRAP5b levels increased significantly in controls (+20 and +10%, respectively). In the GnRH group, suppression of FSH secretion did not reduce serum CTX or TRAP5b levels; rather, both markers also increased in these women (+34 and +15%, respectively; P = 0.161 and 0.266 for comparison of percent changes between groups). Conclusions: This direct interventional study demonstrates that FSH does not regulate bone resorption in postmenopausal women.

Original languageEnglish (US)
Pages (from-to)5063-5068
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume95
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Follicle Stimulating Hormone
Bone Resorption
Bone
Acid Phosphatase
Gonadotropin-Releasing Hormone
Aromatase Inhibitors
Estrogens
letrozole
Serum
Leuprolide
Menopause
Biomarkers
Placebos
Outcome Assessment (Health Care)
Prospective Studies
Injections
Research
Tartrate-Resistant Acid Phosphatase
tartaric acid
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. / Drake, Matthew M; McCready, Louise K.; Hoey, Kelley A.; Atkinson, Elizabeth J.; Khosla, Sundeep.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 95, No. 11, 11.2010, p. 5063-5068.

Research output: Contribution to journalArticle

@article{7ec407dfccd44a6bb93b9bf060981815,
title = "Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women",
abstract = "Context: It has recently been proposed that the increase in bone resorption after the menopause may not be due principally to estrogen deficiency but rather to the concomitant increase in circulating FSH levels. Objective: The objective of the study was to test whether suppression of FSH secretion in postmenopausal women reduces levels of bone resorption markers. Design: This was a prospective study. Setting: The study was conducted at a clinical research unit. Participants and Interventions: Postmenopausal women were treated with a GnRH agonist (leuprolide acetate, 7.5 mg im every 28 d; n = 21) or placebo injections (control; n = 20). Both groups received the aromatase inhibitor, letrozole, 2.5 mg/d, to eliminate variations in endogenous estrogen levels as a confounder. Main Outcome Measures: Serum FSH and bone resorption markers [serum C-terminal telopeptide of type I collagen (CTX) and tartrate-resistant acid phosphatase 5b (TRAP5b)] at d 105 (3.5 months) of treatment as compared with baseline. Results: Compared with baseline, serum FSH levels did not change significantly in controls (+6{\%}) but were reduced (-86{\%}, into the premenopausal range) in the GnRH group. Due to the aromatase inhibitor-induced reduction in estrogen production, serum CTX and TRAP5b levels increased significantly in controls (+20 and +10{\%}, respectively). In the GnRH group, suppression of FSH secretion did not reduce serum CTX or TRAP5b levels; rather, both markers also increased in these women (+34 and +15{\%}, respectively; P = 0.161 and 0.266 for comparison of percent changes between groups). Conclusions: This direct interventional study demonstrates that FSH does not regulate bone resorption in postmenopausal women.",
author = "Drake, {Matthew M} and McCready, {Louise K.} and Hoey, {Kelley A.} and Atkinson, {Elizabeth J.} and Sundeep Khosla",
year = "2010",
month = "11",
doi = "10.1210/jc.2010-1103",
language = "English (US)",
volume = "95",
pages = "5063--5068",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women

AU - Drake, Matthew M

AU - McCready, Louise K.

AU - Hoey, Kelley A.

AU - Atkinson, Elizabeth J.

AU - Khosla, Sundeep

PY - 2010/11

Y1 - 2010/11

N2 - Context: It has recently been proposed that the increase in bone resorption after the menopause may not be due principally to estrogen deficiency but rather to the concomitant increase in circulating FSH levels. Objective: The objective of the study was to test whether suppression of FSH secretion in postmenopausal women reduces levels of bone resorption markers. Design: This was a prospective study. Setting: The study was conducted at a clinical research unit. Participants and Interventions: Postmenopausal women were treated with a GnRH agonist (leuprolide acetate, 7.5 mg im every 28 d; n = 21) or placebo injections (control; n = 20). Both groups received the aromatase inhibitor, letrozole, 2.5 mg/d, to eliminate variations in endogenous estrogen levels as a confounder. Main Outcome Measures: Serum FSH and bone resorption markers [serum C-terminal telopeptide of type I collagen (CTX) and tartrate-resistant acid phosphatase 5b (TRAP5b)] at d 105 (3.5 months) of treatment as compared with baseline. Results: Compared with baseline, serum FSH levels did not change significantly in controls (+6%) but were reduced (-86%, into the premenopausal range) in the GnRH group. Due to the aromatase inhibitor-induced reduction in estrogen production, serum CTX and TRAP5b levels increased significantly in controls (+20 and +10%, respectively). In the GnRH group, suppression of FSH secretion did not reduce serum CTX or TRAP5b levels; rather, both markers also increased in these women (+34 and +15%, respectively; P = 0.161 and 0.266 for comparison of percent changes between groups). Conclusions: This direct interventional study demonstrates that FSH does not regulate bone resorption in postmenopausal women.

AB - Context: It has recently been proposed that the increase in bone resorption after the menopause may not be due principally to estrogen deficiency but rather to the concomitant increase in circulating FSH levels. Objective: The objective of the study was to test whether suppression of FSH secretion in postmenopausal women reduces levels of bone resorption markers. Design: This was a prospective study. Setting: The study was conducted at a clinical research unit. Participants and Interventions: Postmenopausal women were treated with a GnRH agonist (leuprolide acetate, 7.5 mg im every 28 d; n = 21) or placebo injections (control; n = 20). Both groups received the aromatase inhibitor, letrozole, 2.5 mg/d, to eliminate variations in endogenous estrogen levels as a confounder. Main Outcome Measures: Serum FSH and bone resorption markers [serum C-terminal telopeptide of type I collagen (CTX) and tartrate-resistant acid phosphatase 5b (TRAP5b)] at d 105 (3.5 months) of treatment as compared with baseline. Results: Compared with baseline, serum FSH levels did not change significantly in controls (+6%) but were reduced (-86%, into the premenopausal range) in the GnRH group. Due to the aromatase inhibitor-induced reduction in estrogen production, serum CTX and TRAP5b levels increased significantly in controls (+20 and +10%, respectively). In the GnRH group, suppression of FSH secretion did not reduce serum CTX or TRAP5b levels; rather, both markers also increased in these women (+34 and +15%, respectively; P = 0.161 and 0.266 for comparison of percent changes between groups). Conclusions: This direct interventional study demonstrates that FSH does not regulate bone resorption in postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=77958081869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958081869&partnerID=8YFLogxK

U2 - 10.1210/jc.2010-1103

DO - 10.1210/jc.2010-1103

M3 - Article

C2 - 20610587

AN - SCOPUS:77958081869

VL - 95

SP - 5063

EP - 5068

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -